Navigation Links
ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
Date:10/19/2011

EXTON, Pa., Oct. 19, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2011 are expected to be released on Thursday, October 27, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 8:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2011 third quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until November 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma a
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
2. ViroPharma Announces Additional Securities Repurchase Program
3. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
4. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
5. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
6. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
7. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
8. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
9. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
10. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
11. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Systems U.S.A., Inc. is pleased to announce the FDA ... Wireless. This new wireless version of the company,s ... quality in a lightweight design for enhanced versatility and ... imaging applications. The FDR D-EVO Wireless will be featured ...
... presented from pooled analyses of the STELARA® (ustekinumab) psoriasis ... STELARA and rates of adverse events remained consistent and ... plaque psoriasis receiving up to four years of treatment. ... placebo-controlled Phase 3 trials across patient populations on three ...
Cached Medicine Technology:FUJIFILM's FDR D-EVO™ Wireless Now Available in the U.S. 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 2New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 3New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 4New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 5New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 6New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 7New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 8New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 9New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 10New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis 11
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... their effort to ensure,this generation of veterans is ... partnered with St. Johns, University School,of Risk Management, ... (IICF) on a three-day "Warriors to Work" Insurance,Industry ... wounded,warriors, most of whom were from the New ...
... is the best available option for people with hemochromatosis ... is often dismissed as a primitive form of medicine, ... of bad humors by draining the life-sustaining fluid. , ... is still the preferred means of treatment. , Hemochromatosis ...
... quality of care, communication and productivity,to new levels, while improving ... ... disciplines of care, PITTSBURGH, Aug. 25 Vocollect Healthcare ... retirement,community located in Wyomissing, Pennsylvania, will deploy AccuNurse(R),voice- assisted care ...
... Fitness tops competition on Inc. 5000 list ... rakes in revenue and new members, DOVER, N.H., ... for its "Judgment Free" atmosphere and friendly prices, earned,the ... 2008 list of,the 5,000 fastest-growing private businesses in the ...
... be racing faster this fall for every medical student in ... student and resident must pass will be delivered in a ... a skill that some say has become an Achilles heel ... doctors and residents out there taking this test know they ...
... and supplies to the EMS market, announced today the release of ... design first introduced to the EMS community in 1999. , ... ... [Hartwell Medical], a leading supplier of [emergency medical equipment] and ...
Cached Medicine News:Health News:Wounded Warrior Project (WWP), St. John's University, and Insurance Industry Charitable Foundation Partner to Assist Wounded Warriors 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 2Health News:The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels 3Health News:N.H.-Based Health Club Operator Sets The Industry's Pace 2Health News:Listen up! 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 2Health News:Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market 3
... Stratasis TF is a minimally ... treat stress urinary incontinence resulting from ... sphincter deficiency. The Stratasis TF Kit ... antegrade or retrograde placement. Supplied ...
... Used to dilate the ... medium to assess possible submucosal ... a topical anesthetic in the ... passage by, or dislodgment of ...
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
Medicine Products: